SAN DIEGO, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that it will release its second quarter 2015 financial results before the market opens on Thursday, August 13, 2015.
About Neothetics, Inc.
Neothetics is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. The lead product candidate, LIPO-202, is for central abdominal bulging due to subcutaneous fat in non-obese subjects, an indication for which there is no FDA-approved drug. If approved, LIPO-202 may be a best-in-class non-surgical, non-ablative procedure and first-in-class injectable formulation for localized fat reduction and body contouring. For more information on Neothetics, please visit www.neothetics.com.
Neothetics, LIPO-202, LIPO-102 and the Neothetics logo are trademarks or registered trademarks of Neothetics, Inc. Other names and brands may be claimed as the property of others.
CONTACT: COMPANY CONTACT: Susan A. Knudson Chief Financial Officer 858-750-1008 firstname.lastname@example.org INVESTOR CONTACT: Fara Berkowitz, PharmD Investor Relations and Corporate Strategy email@example.com MEDIA CONTACT: Margaux Stack-Babich Canale Communications 619-849-5385 firstname.lastname@example.org